In preclinical studies, genetic and pharmacological inhibition of phosphoinositide 3-kinase (PI3K)γ blocked the accumulation of immunosuppressive MDSCs in TME [115] and skewed TAMs to produce higher levels of proinflammatory cytokines (e.g., TNFα, IL-12), finally resulting in significant reduction in tumor progression [115,116]. The gene discussed is TNF; the disease is neoplasm.